
Crescent Biopharma, Inc.: stock overview
Price
$13.00
November 20, 2026Market cap $506M
What Ploutos Investor adds for Crescent Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Crescent Biopharma had revenue of $15M over the last 12 months and a net loss of $109M. Revenue grew by 1.3% a year on average over the last 5 years. It holds more cash than debt, by $289M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $506M
- 38.90M shares
- P/E
- –
- Revenue, 12 months
- $15M
- +1.3% a year over 5 years
- Net margin
- -727.6%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+1,102.4% a year over 2 years
Fiscal years in figures
CBIO's revenue, profit, cash flow and dividend with each year-end price, from 2012 to 2021, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap
- $506M
- Enterprise value
- $216M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 14.4
- P/B
- 1.9
- FCF yield
- –
- Earnings yield
- –
Profitability
- Operating margin
- -1,216.6%
- Net margin
- -727.6%
- ROIC
- -76.6%
- ROIC, 5-year average
- -64.1%
- ROE
- -58.0%
Growth
- Revenue, yearly change
- +3,193.0%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +1.3%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $289M
- Total debt
- $2.5M
- Of which operating leases
- $2.5M
- Net cash
- $289M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 12.57
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- -34.6%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- CRESCENT BIOPHARMA, INC.
- CIK
- 1253689
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 38.90M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with CBIO
- JNJJohnson & Johnson+0,00%Compare with CBIO
- ABBVAbbVie+0,00%Compare with CBIO
- UNHUnitedHealth+0,00%Compare with CBIO
- MRKMerck & Company+0,00%Compare with CBIO
- AMGNAmgen+0,00%Compare with CBIO
- TMOThermo Fisher Scientific+0,00%Compare with CBIO
- ABTAbbott Laboratories+0,00%Compare with CBIO
The full analysis
What do Crescent Biopharma's filings show?
These are Crescent Biopharma's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is CBIO's market cap?
Crescent Biopharma, Inc.'s market cap is $506M, at a price of $13.00 on November 20, 2026 and 38.90M shares.
How much revenue does CBIO have?
Crescent Biopharma had revenue of $15M over the last 12 months. Over the last 5 years it changed by +1.3% a year on average.
Does CBIO pay a dividend?
No. Crescent Biopharma paid no regular dividend over the last 12 months.
Where do the figures come from?
From Crescent Biopharma, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.